Publications
Second-line treatment in inoperable pancreatic adenocarcinoma: A systematic review and synthesis of all clinical trials
Abstract
There remains uncertainty regarding the optimal second-line chemotherapy in advanced pancreatic ductal adenocarcinoma (PDAC). The current recommendation of 5-fluorouracil and oxaliplatin may not be relevant in current practice, as FOLFIRINOX (5-fluorouracil, leucovorin, irinotecan and oxaliplatin) has become a more popular first line therapy in fit patients. The majority of studies in this setting are single-arm Phase II trials with significant heterogeneity of patient populations, treatments and outcomes. In this review, we sought to systematically review and synthesise all prospective data available for the second-line treatment of advanced PDAC.
| Type | Journal |
|---|---|
| ISBN | 1879-0461 (Electronic) 1040-8428 (Linking) |
| Authors | Nagrial, A. M. ; Chin, V. T. ; Sjoquist, K. M. ; Pajic, M. ; Horvath, L. G. ; Biankin, A. V. ; Yip, D.; |
| Responsible Garvan Author | (missing name) |
| Publisher Name | CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY |
| Published Date | 2015-12-01 |
| Published Volume | 96 |
| Published Issue | 3 |
| Published Pages | 483-97 |
| Status | Published in-print |
| URL link to publisher's version | http://www.ncbi.nlm.nih.gov/pubmed/26481952 |
| OpenAccess link to author's accepted manuscript version | https://publications.gimr.garvan.org.au/open-access/13240 |